secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mersana Therapeutics, Inc. (—)
CIK:        0001442836
Form:       8-K
Filed at:   2023-09-06T23:59:59+00:00
Accession:  0001104659-23-098499
Event type: leadership
Sentiment:  neutral
Materiality: 0.80
Item codes: 5.02, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

CEO Protopapas retires; Dr. Martin Huber takes over; CMO Dr. Arvin Yang departs
-------------------------------------------------------------------------------

- CEO Anna Protopapas retires effective Sept 10; remains on board; receives prorated 2023 bonus and extended equity vesting.
- Dr. Martin Huber appointed President & CEO effective Sept 11; base salary $625K, target bonus 60%, option for 1M shares, RSU for 667K shares.
- CMO Dr. Arvin Yang last day Sept 29; severance of 9 months base salary plus COBRA premiums.
- Brian DeSchuytner named SVP, COO & CFO; Mohan Bala named SVP, Chief Development Officer; Ashish Mandelia VP, Chief Accounting Officer.
- Compensation Committee granted 330,000 RSUs as retention awards to senior management, vesting Oct 1, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1442836/000110465923098499/0001104659-23-098499-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1442836/000110465923098499/tm2325490d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-098499

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer